| Title |
A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, June 2013
|
| DOI | 10.2147/ndt.s40503 |
| Pubmed ID | |
| Authors |
Jing Chen, Zheng Lu, Mingyuan Zhang, Jie Zhang, Xiaodong Ni, Xuefeng Jiang, Heding Xu, Anisha Heeramun-Aubeeluck, Qiaoyan Hu, Hua Jin, John M Davis |
| Abstract |
A significant number of mania patients fail to respond to current pharmacotherapy, thereby there is need for novel augmentation strategies. The results of some early studies showed the effectiveness of cholinomimetics in the treatment of mania. One open case series suggested the efficacy of donepezil in the treatment of bipolar disorder. Our aim was to explore whether an oral cholinesterase inhibitor, donepezil, administered during a 4-week treatment period, would benefit patients with acute mania. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 16% |
| Researcher | 5 | 16% |
| Student > Master | 3 | 10% |
| Student > Bachelor | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 5 | 16% |
| Unknown | 9 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Psychology | 4 | 13% |
| Nursing and Health Professions | 2 | 6% |
| Neuroscience | 2 | 6% |
| Other | 0 | 0% |
| Unknown | 11 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2013.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,584
of 3,132 outputs
Outputs of similar age
#181,530
of 206,481 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#45
of 54 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,481 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.